The global pulmonary drug delivery technology market is projected to grow at a CAGR of approximately 5% over the next five ...
Reinventing pulmonary care medically improves early diagnosis and interdisciplinary management for complex patients with COPD ...
Medication nonadherence among people with chronic obstructive pulmonary disease (COPD) is a result of affordability and lack ...
Medication nonadherence among people with chronic obstructive pulmonary disease (COPD) is a result of affordability and lack of knowledge about medications, among other factors, and leads to increased ...
MedPage Today on MSN
Inhaled Vasodilator Slows Lung Function Decline in Idiopathic Pulmonary Fibrosis
Clinical worsening also occurred less frequently with treprostinil ...
Medication nonadherence among people with chronic obstructive pulmonary disease (COPD) is a result of affordability and lack of knowledge about ...
New research from UCLA Health suggests that certain inhalers used to treat chronic obstructive pulmonary disease (COPD) are not only less harmful to the environment but can also lead to slightly ...
Medication nonadherence among people with chronic obstructive pulmonary disease (COPD) is a result of affordability and lack ...
Key market opportunities in the inhaler solution market include the rising demand driven by increased respiratory disorders ...
Dry Powder Inhalers: A Double Win for COPD and Environment By Dennis Thompson HealthDay ReporterTUESDAY, Feb. 24, 2026 (HealthDay News) — Dry powder inhalers might provide a double benefit for people ...
Umeclidinium-vilanterol is associated with improved clinical outcomes in symptomatic patients with chronic obstructive pulmonary disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results